Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.
- DOI
- 10.1002/cncr.70459
- Published
- 2026 Jul 1
- Container
- Cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cncr.70459,
title = {Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.},
author = {Lin X and Liu Z and Yang C and Zhuang J and Wei N and Cui T and Zheng W and Ye F and Ding X and Chen M and Han B},
year = {2026},
journal = {Cancer},
doi = {10.1002/cncr.70459},
url = {https://doi.org/10.1002/cncr.70459}
}RIS
TY - JOUR TI - Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study. AU - Lin X AU - Liu Z AU - Yang C AU - Zhuang J AU - Wei N AU - Cui T AU - Zheng W AU - Ye F AU - Ding X AU - Chen M AU - Han B PY - 2026 JO - Cancer DO - 10.1002/cncr.70459 UR - https://doi.org/10.1002/cncr.70459 ER -
APA
X, L., Z, L., C, Y., J, Z., N, W., T, C., W, Z., F, Y., X, D., M, C., & B, H. (2026). Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.. Cancer. https://doi.org/10.1002/cncr.70459
Source records
- pubmed · retrieved 2026-09-25T13:02:12.687Z